146 related articles for article (PubMed ID: 28504025)
1. The preclinical discovery of vosaroxin for the treatment of acute myeloid leukemia.
Paubelle E; Zylbersztejn F; Thomas X
Expert Opin Drug Discov; 2017 Jul; 12(7):747-753. PubMed ID: 28504025
[TBL] [Abstract][Full Text] [Related]
2. Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.
Hotinski AK; Lewis ID; Ross DM
Expert Opin Pharmacother; 2015 Jun; 16(9):1395-402. PubMed ID: 25958926
[TBL] [Abstract][Full Text] [Related]
3. The safety and efficacy of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia - a critical review.
Short NJ; Ravandi F
Expert Rev Hematol; 2016 Jun; 9(6):529-34. PubMed ID: 27158854
[TBL] [Abstract][Full Text] [Related]
4. Molecular and Pharmacologic Properties of the Anticancer Quinolone Derivative Vosaroxin: A New Therapeutic Agent for Acute Myeloid Leukemia.
Jamieson GC; Fox JA; Poi M; Strickland SA
Drugs; 2016 Sep; 76(13):1245-1255. PubMed ID: 27484675
[TBL] [Abstract][Full Text] [Related]
5. Targeting acute myeloid leukemia with TP53-independent vosaroxin.
Benton CB; Ravandi F
Future Oncol; 2017 Jan; 13(2):125-133. PubMed ID: 27615555
[TBL] [Abstract][Full Text] [Related]
6. Vosaroxin : a novel antineoplastic quinolone.
Abbas JA; Stuart RK
Expert Opin Investig Drugs; 2012 Aug; 21(8):1223-33. PubMed ID: 22724917
[TBL] [Abstract][Full Text] [Related]
7. Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
Liu F; Knight T; Su Y; Edwards H; Wang G; Wang Y; Taub JW; Lin H; Sun L; Ge Y
Target Oncol; 2019 Jun; 14(3):351-364. PubMed ID: 31115744
[TBL] [Abstract][Full Text] [Related]
8. Vosaroxin: a new valuable tool with the potential to replace anthracyclines in the treatment of AML?
Freeman C; Keane N; Swords R; Giles F
Expert Opin Pharmacother; 2013 Jul; 14(10):1417-27. PubMed ID: 23688047
[TBL] [Abstract][Full Text] [Related]
9. Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study.
Ravandi F; Ritchie EK; Sayar H; Lancet JE; Craig MD; Vey N; Strickland SA; Schiller GJ; Jabbour E; Erba HP; Pigneux A; Horst HA; Recher C; Klimek VM; Cortes J; Roboz GJ; Odenike O; Thomas X; Havelange V; Maertens J; Derigs HG; Heuser M; Damon L; Powell BL; Gaidano G; Carella AM; Wei A; Hogge D; Craig AR; Fox JA; Ward R; Smith JA; Acton G; Mehta C; Stuart RK; Kantarjian HM
Lancet Oncol; 2015 Sep; 16(9):1025-1036. PubMed ID: 26234174
[TBL] [Abstract][Full Text] [Related]
10. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Lancet JE; Roboz GJ; Cripe LD; Michelson GC; Fox JA; Leavitt RD; Chen T; Hawtin R; Craig AR; Ravandi F; Maris MB; Stuart RK; Karp JE
Haematologica; 2015 Feb; 100(2):231-7. PubMed ID: 25381131
[TBL] [Abstract][Full Text] [Related]
11. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.
Stuart RK; Cripe LD; Maris MB; Cooper MA; Stone RM; Dakhil SR; Turturro F; Stock W; Mason J; Shami PJ; Strickland SA; Costa LJ; Borthakur G; Michelson GC; Fox JA; Leavitt RD; Ravandi F
Br J Haematol; 2015 Mar; 168(6):796-805. PubMed ID: 25403830
[TBL] [Abstract][Full Text] [Related]
12. Homologous recombination repair is essential for repair of vosaroxin-induced DNA double-strand breaks.
Hawtin RE; Stockett DE; Wong OK; Lundin C; Helleday T; Fox JA
Oncotarget; 2010 Nov; 1(7):606-619. PubMed ID: 21317456
[TBL] [Abstract][Full Text] [Related]
13. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.
Lancet JE; Ravandi F; Ricklis RM; Cripe LD; Kantarjian HM; Giles FJ; List AF; Chen T; Allen RS; Fox JA; Michelson GC; Karp JE
Leukemia; 2011 Dec; 25(12):1808-14. PubMed ID: 21760592
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of radiosensitivity by the novel anticancer quinolone derivative vosaroxin in preclinical glioblastoma models.
Gravina GL; Mancini A; Mattei C; Vitale F; Marampon F; Colapietro A; Rossi G; Ventura L; Vetuschi A; Di Cesare E; Fox JA; Festuccia C
Oncotarget; 2017 May; 8(18):29865-29886. PubMed ID: 28415741
[TBL] [Abstract][Full Text] [Related]
15. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine.
Walsby EJ; Coles SJ; Knapper S; Burnett AK
Haematologica; 2011 Mar; 96(3):393-9. PubMed ID: 21134979
[TBL] [Abstract][Full Text] [Related]
16. Vosaroxin and vosaroxin plus low-dose Ara-C (LDAC) vs low-dose Ara-C alone in older patients with acute myeloid leukemia.
Dennis M; Russell N; Hills RK; Hemmaway C; Panoskaltsis N; McMullin MF; Kjeldsen L; Dignum H; Thomas IF; Clark RE; Milligan D; Burnett AK
Blood; 2015 May; 125(19):2923-32. PubMed ID: 25805811
[TBL] [Abstract][Full Text] [Related]
17. Metabolism and disposition of the anticancer quinolone derivative vosaroxin, a novel inhibitor of topoisomerase II.
Nijenhuis CM; Lucas L; Rosing H; Huitema ADR; Mergui-Roelvink M; Jamieson GC; Fox JA; Mould DR; Schellens JHM; Beijnen JH
Invest New Drugs; 2017 Aug; 35(4):478-490. PubMed ID: 28138829
[TBL] [Abstract][Full Text] [Related]
18. Radiosensitization by the novel DNA intercalating agent vosaroxin.
Gordon IK; Graves C; Kil WJ; Kramp T; Tofilon P; Camphausen K
Radiat Oncol; 2012 Feb; 7():26. PubMed ID: 22369205
[TBL] [Abstract][Full Text] [Related]
19. Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
Hawtin RE; Stockett DE; Byl JA; McDowell RS; Nguyen T; Arkin MR; Conroy A; Yang W; Osheroff N; Fox JA
PLoS One; 2010 Apr; 5(4):e10186. PubMed ID: 20419121
[TBL] [Abstract][Full Text] [Related]
20. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
